Psoriasis
Conditions
Interventions
Monotherapy group (Treated with secukinumab injection only):None
Combination therapy group (Treated with secukinumab injection in combination with Compound Qingdai Capsules):None
Sponsors
Gong'an County People's Hospital, Hubei Province
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18–75 years with a confirmed diagnosis of moderate-to-severe plaque psoriasis; 2. Currently receiving secukinumab treatment for at least 3–6 months with stable disease; 3. Currently receiving oral compound indigo naturalis capsules; 4. Has signed the informed consent form and is willing to participate in a one-year follow-up.
Exclusion criteria
Exclusion criteria: 1. Subjects who were forced to discontinue medication due to serious adverse reactions; 2. Subjects who immediately switched to other biologics or systemic immunosuppressants after discontinuation; 3. Subjects with past or current serious active infections (e.g., active tuberculosis); combined with severe diseases of vital organs and tissues (e.g., heart, brain, lungs, liver, kidneys, etc.); combined with severe cardiac, hepatic, or renal insufficiency, or malignant tumors; 4. Subjects with a history of hypersensitivity to the active ingredients or any excipients of the study medications, or a history of latex allergy; 5. Other circumstances deemed by the investigator to be unsuitable for participation in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relapse cycle; | — |
Secondary
| Measure | Time frame |
|---|---|
| PASI score ;BSA score ;PGA score;DLQI score;PSSI score;mNAPSI score;sPGA-G score; | — |
Countries
China
Contacts
Public ContactJinfang Chen
Gong'an County People's Hospital
Outcome results
None listed